Tag Archives: Tendering and procurement

Guangdong Drug Exchange Center Opens Linkage Price Confirmation Window for Listed Drugs – Batch 20260917 Targets Above‑Benchmark VBP Winners and “Four‑Same” Products, With Delisting and Disqualification Risks for Non‑Compliance

Notice Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Action	Linkage price viewing & confirmation for selected listed drugs
Batch	20260917
Product Scope	① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system)
Confirmation Window	Immediate – 20 Sep 2026, 17:00
Platform	Guangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login)
Policy Basis	National drug price governance requirements

Confirmation Paths & Consequences

Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
“Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.

Sector Background

Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
“Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).

Market Impact & Outlook

Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264

Hunan Implements National Coronary Stent VBP Second‑Round Continuation Results – Province‑Wide Execution From 1 October 2026 With Red/Yellow Price Guardrails

Regulatory Milestone

Item	Detail
Issuing Agency	Hunan Provincial Healthcare Security Administration
Document	Xiang Yi Bao Han [2026] No. 37 (issued 9 Sep 2026)
Policy Type	Provincial implementation of national VBP second‑round continuation selection results
Product Scope	Coronary stent consumables – selected products per the attached national list
Effective Date	1 October 2026 (province‑wide unified execution)
Procurement Cycle	Through 30 June 2029; first contract year covers 1 Oct 2026 – 31 Dec 2027; agreements signed annually
Key Deadlines	Supplier registration & distribution setup on the Hunan Medical Procurement Platform by 30 Sep 2026; tripartite purchase‑sale agreements signed by 1 Nov 2026

Procurement Mechanism & Compliance Requirements

Participating Institutions: All public medical institutions (including military facilities) and all institutions that reported volumes are required to purchase and use selected products; other medical‑insurance‑contracted institutions are encouraged to participate.
Agreed Volumes: Annual contracted volumes are the quantities confirmed by hospitals in the procurement system (communicated separately to hospitals and winning suppliers). The first‑year volume is scaled at 15/12 of the annual agreement (rounded), reflecting the 15‑month initial contract period; non‑integer results are rounded.
Beyond‑Agreement Supply: Purchases exceeding the agreed volume must still be supplied by winning companies at the selected price until the end of the procurement cycle.
Platform‑Only Trading: All transactions must run through the Hunan Medical Procurement Platform; offline procurement, secondary price negotiation and any form of discount are strictly prohibited.
Usage Floor: Selected products must account for no less than 80% of total same‑category procurement and usage volume during the agreement period; hospitals may buy other price‑appropriate products only after fulfilling contracted volumes.
No Hidden Fees: Hospitals (including third‑party service providers) may not charge any additional fees for market entry, inventory or clinical use of selected stents, and may not block access citing cost control, product‑count limits, unreported volumes, quality deposits or distributor account caps.
Supply Responsibility: Winning companies are the first‑line responsible party for quality and supply, and must maintain emergency stockpiles and report capacity shortfalls to the provincial bureau in advance; prior distribution relationships are automatically cleared upon implementation. Non‑compliance (supply failure, quality defects) will be escalated to the Joint Procurement Office, with penalties, disqualification and credit‑system consequences applied.

Price Guardrails – Red/Yellow Label Monitoring

Under the “price‑procurement linkage” mechanism, non‑selected coronary stents listed on the platform at elevated prices will carry warning labels benchmarked to the highest selected price, with procurement risk alerts issued to hospitals:

Product Category	Yellow Label Threshold (≥1.8× highest selected price)	Red Label Threshold (≥2.5× highest selected price)
Non‑selected coronary drug‑eluting alloy stents	¥1,708 / unit	¥2,372 / unit
Non‑selected coronary drug‑eluting stainless‑steel stents	¥1,526 / unit	¥2,120 / unit

Selected‑product awarded prices and company‑level results were not disclosed in the provincial notice (referenced to the national attachment list).

Market Impact & Outlook

Continuity Signal: The second‑round continuation locks the nationally pioneered coronary stent VBP framework in place through mid‑2029, extending price certainty for hospitals and winning manufacturers after the landmark first round that reset China’s stent market.
Pressure on Non‑Selected Products: The explicit red/yellow label price ceilings (1.8× / 2.5× the top awarded price) effectively cap how long premium‑priced non‑selected stents can compete in Hunan, pushing hospitals toward selected products and squeezing margin room for out‑of‑award brands.
Hospital Enforcement Teeth: Execution progress is subject to “monthly monitoring and annual evaluation,” and is written into medical‑insurance designated‑hospital agreement assessments; hospitals with serious lag, unfulfilled volumes or heavy use of high‑priced non‑selected products face contractual consequences.
Supplier Reset: Automatic clearing of prior distribution relationships forces winning companies to rebuild logistics coverage within weeks of the notice, while distributor performance (order response, delivery) becomes a compliance exposure for manufacturers.
National Alignment: The notice stipulates that any national policy adjustments during the cycle will be followed accordingly, keeping Hunan’s execution synchronized with the central healthcare security authority’s continuation‑procurement playbook.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding procurement execution timelines, contract volumes, supply arrangements and price‑monitoring enforcement for the coronary stent VBP continuation in Hunan Province. Actual outcomes may differ due to risks including national policy adjustments, supplier capacity and distribution readiness, hospital compliance dynamics, and quality or supply disruptions. Company‑level awarded prices and volumes are not disclosed in the provincial notice.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260910_34061201.html

Yunnan Lists Coronary Stent Procurement Winners for Second Round

Leave a reply

Kunming, Sept 4, 2026 — Yunnan’s Government Procurement and Concession Center announced the online listing of selected products for the second round of national coronary stent volume-based procurement, launching a new procurement cycle running from Sept 15, 2026, to June 30, 2029, while terminating transaction eligibility for products under the previous agreement.

Policy Snapshot

Attribute	Detail
Issuers	Yunnan Government Procurement and Concession Center; Yunnan Provincial Medical Security Bureau
Document	Notice on the Work of Hanging Selected Products in the Second Round of National Coronary Stent Centralized Procurement
Platform	Yunnan Medical Insurance Information Platform — Drug and Medical Consumables Procurement Management Subsystem
Procurement cycle	Sept 15, 2026 – June 30, 2029
Agreement structure	Tripartite (one-year renewable contracts)
Key actions	Online listing of selected products; price governance for non-selected products

Key Provisions

Selected product listing — Winning products are listed on the procurement subsystem for transaction and settlement. Products listed under the previous agreement period are simultaneously delisted.
Distributor designation — Selected enterprises independently designate distribution partners through the procurement subsystem and establish delivery relationships. Annual tripartite agreements are signed to define rights and obligations.
Price governance — Non-selected products with excessively high listed prices are assigned “red/yellow” warning labels. Enterprises receiving targeted notifications must adjust prices accordingly; those without notifications are outside this round’s price governance scope.
Dynamic listing compliance — Non-selected products must follow the dynamic listing rules under Yunnan Medical Security Bureau [2022] No. 92 for application and price adjustment.
System registration — Enterprises without existing accounts must complete registration on the procurement subsystem per the March 20, 2024, platform notice.

Market Impact Analysis

The nearly three-year procurement cycle provides supply certainty for coronary stent manufacturers and cardiology departments across Yunnan’s public hospital network. By automatically terminating the previous agreement and activating the new second-round listings, regulators are ensuring a clean transition without overlapping transaction eligibility that could confuse hospital procurement officers.

The “red/yellow” warning system for non-selected products is a particularly consequential market-shaping tool. By flagging overpriced non-winners, the mechanism extends the price compression effect of national volume-based procurement beyond the selected supplier pool, pressuring the entire competitive set to align with national benchmarks or risk exclusion from hospital formularies. This creates a de facto price ceiling for the coronary stent market in Yunnan, compressing margins for both domestic and international manufacturers that failed to secure selected status.

For selected enterprises, the ability to independently designate distributors offers operational flexibility, though the annual tripartite agreement structure introduces yearly renegotiation leverage points for hospitals. The requirement for enterprises without platform accounts to register before participating ensures full traceability in the procurement chain but may delay market entry for smaller manufacturers unfamiliar with Yunnan’s digital procurement infrastructure.

Forward-Looking Statement

Industry analysts expect the Sept 15 launch to serve as a template for other provincial procurement centers rolling out the national coronary stent second-round agreement in the coming weeks. The three-year cycle ending in mid-2029 gives manufacturers long-term volume visibility, though the annual distributor agreement renewals create recurring compliance checkpoints. The red/yellow price warning system is likely to be replicated across other high-value device categories—such as orthopedic implants and pacemakers—as provincial regulators seek to manage non-selected product pricing without resorting to formal delisting. Companies with coronary stent portfolios should monitor Yunnan’s platform closely, as the dynamic listing rules for non-selected products may trigger additional price adjustment mandates before year-end.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27794&CatalogId=3